Medical Therapy. Efficacy or Lack of Efficacy

Propranolol Therapy for Congenital Chylothorax

Roxane Handel-Orefice, Bevin Midura, June K. Wu, Elvira Parravicini, Russell S. Miller, Carrie J. ShawberColumbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Morgan Stanley Children’s HospitalUnited States PediatricsPediatrics 2023; 151: DOI: 10.1542/peds.2022-058555 AbstractCongenital chylothorax is a rare and often severe anomaly without well-established medical therapies. Previously, propranolol use in patients with lymphatic malformations […]

Propranolol Therapy for Congenital Chylothorax Read More »

Diagnosis and treatment of diffuse pulmonary lymphangioma in children: A case report

Xiaopu Sun, Chengyu Lu, Zhanhang Huang, Jiaxing Xu, Huiyi Zhu, Sen Yang, Deihui ChenThe First Affiliated Hospital of Guangzhou Medical University.China Experimental and Therapeutic MedicineExp Ther Med 2023; 25: DOI: 10.3892/etm.2023.11874 AbstractThe present study aimed to investigate the clinical characteristics of diffuse pulmonary lymphangioma (DPL) in children to improve the diagnosis and treatment of this disease.

Diagnosis and treatment of diffuse pulmonary lymphangioma in children: A case report Read More »

Effects of a Long-Term Wearable Activity Tracker-Based Exercise Intervention on Cardiac Morphology and Function of Patients with Cystic Fibrosis

Maria Anifanti, Stavros Giannakoulakos, Elpis Hatziagorou, Asterios Kampouras, John Tsanakas, Asterios Deligiannis, Evangelia KouidiAristotle University of Thessaloniki and Hippokration Hospital. Greece SensorsSensors 2022; 22: DOI: 10.3390/s22134884 AbstractSeveral studies have shown that patients with cystic fibrosis (CF), even at a young age, have pulmonary and cardiac abnormalities. The main complications are cardiac right ventricular (RV) systolic and/or

Effects of a Long-Term Wearable Activity Tracker-Based Exercise Intervention on Cardiac Morphology and Function of Patients with Cystic Fibrosis Read More »

Long-Term Study on Therapeutic Strategy for Treatment of Eisenmenger Syndrome Patients: A Case Series Study

Yi-Ching Liu, Yu-Wen Chen, I-Chen Chen, Yen-Hsien Wu, Shih-Hsing Lo, Jui-Sheng Hsu, Jong-Hau Hsu, Bin-Nan Wu, Yi-Fang Cheng, Zen-Kong DaiKaohsiung Medical University Hospital. Taiwan ChildrenChildren 2022; 9: DOI: 10.3390/children9081217 AbstractEisenmenger syndrome (ES) refers to congenital heart diseases (CHD) with reversal flow associated with increased pulmonary pressure and irreversible pulmonary vascular remodeling. Previous reports showed limited therapeutic

Long-Term Study on Therapeutic Strategy for Treatment of Eisenmenger Syndrome Patients: A Case Series Study Read More »

Safety of chronic high-dose calcium channel blockers exposure in children with pulmonary arterial hypertension

Yan Wu, Fu-Hua Peng, Xin Gao, Xin-Xin Yan, FengWen Zhang, Jiang-Shan Tan, Song Hu, Lu HuaFuwai Hospital and Chinese Academy of Medical Sciences and Peking Union Medical College.China Frontiers in Cardiovascular MedicineFront Cardiovasc Med 2022; DOI: 10.3389/fcvm.2022.918735 AbstractBackground: Chronic calcium channel blockers (CCBs) are indicated in children with idiopathic/heritable pulmonary arterial hypertension (IPAH/HPAH) and positive response to

Safety of chronic high-dose calcium channel blockers exposure in children with pulmonary arterial hypertension Read More »

Assessing the impact of gestational age of donors on the efficacy of amniotic epithelial cell-derived extracellular vesicles in experimental bronchopulmonary dysplasia

Dandan Zhu, Mirja Krause, Tamara Yawno, Gina D. Kusuma, Renate Schwab, Mehri Barabadi, Amina S. Maleken, Siow T. Chan, Rod Hunt, David Greening, Euan M. Wallace, Rebecca LimHudson Institute of Medical Research. Monash University. La Trobe Institute for Molecular Science and La Trobe University. University of Melbourne.Australia Stem Cell Research and TherapyStem Cell Res Ther

Assessing the impact of gestational age of donors on the efficacy of amniotic epithelial cell-derived extracellular vesicles in experimental bronchopulmonary dysplasia Read More »

Home High-Flow Nasal Cannula Therapy in Children with Congenital Heart Disease

Yuka Hanaki, Jun Muneuchi, Junko Yamamoto, Chie Yokota, Junya Ohmura, Hiroki Ezaki, Miwa Yoshino, Ryoko Nakamura, Miho Takeichi, Yuichiro Sugitani, Ryouhei Matsuoka, Hirohito Doi, Mamie Watanabe, Yasukiko TakahashiKyushu Hospital and Japan Community Healthcare Organization. Japan Pediatric CardiologyPediatr Cardiol 2022; 43: 1131-1135DOI: 10.1007/s00246-022-02834-y AbstractHigh-flow nasal cannula (HFNC) therapy has been applied in the perioperative respiratory care for

Home High-Flow Nasal Cannula Therapy in Children with Congenital Heart Disease Read More »

Cardiorespiratory adaptation to low-dose dexamethasone for lung disease in extremely preterm infants: A prospective echocardiographic study

Arvind Sehgal, Marcel F. Nold, Calum T. Roberts, Samuel MenahemMonash Children’s Hospital, Monash Medical Centre and Monash University. Hudson Institute of Medical Research.Australia Journal of PhysiologyJ Physiol 2022; 600: 4361-4373DOI: 10.1113/JP282973 AbstractThe cardiovascular impact of dexamethasone (Dex) is not well understood. Most data are obtained from a 6 week, high-dose regimen, and are limited to findings

Cardiorespiratory adaptation to low-dose dexamethasone for lung disease in extremely preterm infants: A prospective echocardiographic study Read More »

Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis

Jun Yasuhara, Kae Watanabe, Atsuyuki Watanabe, Takuro Shirasu, Yuichi Matsuzaki, Hirofumi Watanabe, Hisato Takagi, Naokata Sumitomo, Toshiki KunoNationwide Children’s Hospital. Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine. University of Tsukuba Hospital. University of Virginia. McGill University. Medical University of South Carolina. Shizuoka Medical Center. Saitama Medical

Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis Read More »

Implementation of an Inhaled Nitric Oxide Weaning Protocol and Stewardship in a Level 4 NICU to Decrease Inappropriate Use

Walid A. Hussain, Deborah S. Bondi, Pooja Shah, Sherwin E. Morgan, Sudhir Sriram, Michael D. SchreiberLoyola University Medical Center. University of Chicago Medicine Comer Children’s Hospital. United States Journal of Pediatric Pharmacology and TherapeuticsJ Pediatr Pharmacol Ther 2022; 27: 284-291DOI: 10.5863/1551-6776-27.3.284 AbstractObjective: Inhaled nitric oxide (iNO) is an effective but expensive treatment of pulmonary hypertension in newborns,

Implementation of an Inhaled Nitric Oxide Weaning Protocol and Stewardship in a Level 4 NICU to Decrease Inappropriate Use Read More »

Scroll to Top